How OnabotulinumtoxinA “Revolutionized” Treatment of Urologic Conditions

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder. Dr. Kaufman is a Professor of urology, Patricia and Rodes Hart Endowed Chair of Urologic Surgery, and Chief of Reconstructive Urology and Pelvic Health at Vanderbilt University Medical Center, Nashville, Tennessee. Read more.

Source: Urology Times, February 16, 2022

URO-1’s Repris System for Injecting Botox Into Bladder

URO-1, based in Winston-Salem, North Carolina, got FDA approval for its Repris Bladder Injection System. The product is designed for delivering Botox injections into the bladder as a treatment option for overactive bladder. The device, which is supposed to make such procedures easier on the physicians and more comfortable on the patients, will be unveiled at the American Urological Association in San Francisco later this month. Read more.

Source: Medgadget, May 9, 20218

Sacral Neuromodulation, Botulinum Show Equal Efficacy

In patients with refractory urgency urinary incontinence (UUI), sacral neuromodulation (InterStim) and onabotulinumtoxinA (Botox) produce similar reductions in mean daily UUI episodes, according to 24-month follow-up data on patients treated in a randomized trial. Investigators in the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial in 2016 reported that botulinum toxin at 6 months of treatment resulted in a “small daily improvement in UUI episodes” that was statistically significant (JAMA 2016; 316:1366–74). Now, in long-term follow-up data on ROSETTA, NIH investigators reported at the International Continence Society annual meeting in Florence, Italy that the two treatments provide similar reductions in mean daily UUI episodes at 24 months. However, botulinum toxin treatment was more likely to provide complete resolution of episodes 6 months after treatment, and it was associated with higher patient satisfaction and treatment endorsement ratings over the 24 months, reported first author Christopher J. Chermansky, MD, assistant professor of urology at the University of Pittsburgh School of Medicine. Read more.

Source: Urology Times, November 14, 2017

Allergan Partners with Urine Incontinence Treatment Company

Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen. Allergan Pharmaceuticals International Ltd., a wholly owned subsidiary of Allergan PLC, has started a phase 2 clinical trial for the treatment of overactive bladder. The trial will combine Botox with a sustained release gel called RTGel, developed by Nasdaq-listed UroGen Pharma Ltd., a clinical stage company developing non-surgical urology treatments. RTGel is a temperature-sensitive substance that changes from a liquid to a gel when it reaches body temperature. These properties enable a slower release of drugs in the body when mixed with the gel. Botox is already in use for treating overactive bladder, since it relaxes the nerves that over-stimulate the bladder muscles and lead to frequent urination. Read more.

Source: CTECH, November 8, 2017

Botox Beats Implant for Urinary Incontinence in Women

For women with bladder incontinence who haven’t been helped by medications or other therapies, Botox injections may help control leakage better than an implanted nerve stimulation device, a new study suggests. However, both treatments are effective, according to doctors who treat the condition. In a head-to-head comparison, women given Botox saw their number of daily urgency incontinent episodes decrease by four, on average, compared to three for women who received the implant, called InterStim. Botox patients also said they had a greater reduction in symptoms and were more satisfied with the treatment, the researchers said. Read more.

Source: HealthDay News, October 4, 2016

Botulinum Toxin (BOTOX®) Injections

You and your doctor need to decide together if trying BOTOX is right for you.

Botulinum toxin (commonly called BOTOX®) is often used in cosmetic procedures. BOTOX is also a relatively new treatment for severe urge incontinence that has not responded to medical therapy. It is also for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. It is only for use in adults who have had an inadequate response to, or are intolerant of, anticholinergic medication. In this treatment, BOTOX is injected directly into the bladder muscle, relaxing it and allowing the bladder to fill with more urine before the urge to urinate strikes.Continue reading→